Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OB756 vs hydroxycarbamide in intermediate‑2/high‑risk myelofibrosis
CTR20211396Phase 3Completed
- Sponsor
- Huadong Medicine
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bewintinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), sponsored by Huadong Medicine. Started Jul 2021; status: completed.
02
Drugs
bewintinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on CTR20211396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211396.